Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Atrial Fibrillation and Ventricular Arrhythmias in ST Segment Elevation Myocardial Infarction: Possibilities of Pharmacotherapy and Non-Pharmacological Treatment

https://doi.org/10.20996/1819-6446-2018-14-4-605-611

Full Text:

Abstract

Atrial fibrillation (AF) is the most common tachyarrhythmia complicating ST segment elevation myocardial infarction (STEMI), while ventricular arrhythmias (VA) can, not only be accompanied by a hemodynamic disorder, but in some cases, worsen its prognosis. The article presents a modern view on risk factors for development of AF (elderly age, left ventricle systolic dysfunction, heart failure, etc.), strategy and tactics of AF treatment in patients with STEMI, the indications for its pharmacological cardioversion and electro-impulse therapy. It is shown that I.V. administration of betablockers and in some cases amiodarone for reducing the frequency of ventricular contractions is advisable. Features and argumentative issues of triple antithrombotic therapy in patients with AF with STEMI, the possibilities and indications for the use of double antithrombotic therapy instead of triple one are described. Clinical significance and peculiarities of treatment of various types of VA have been determined, the role of myocardial revascularization, radiofrequency catheter ablation, normalization of electrolyte imbalance, use of beta-blockers and amiodarone in the prevention and therapy of lifethreatening ventricular arrhythmias has been emphasized. The irrationality, and sometimes the risk of carrying out prophylactic antiarrhythmic therapy for AF and VA in the acute stage of STEMI, as well as the role of the implantable cardioverter-defibrillator in primary prevention of death in certain groups of patients with low left ventricle ejection fraction after myocardial infarction was noted. The value of various antiarrhythmic drugs in their effect on the improvement of prognosis in patients after STEMI is estimated. The material is presented based on modern recommendations for the treatment of patients with STEMI, therapy of AF and VA, prevention of sudden cardiac death, as well as data from several controlled studies and own clinical experience of pharmacotherapy of arrhythmias.

About the Authors

Yu. A. Bunin
Russian Medical Academy of Continuous Professional Education
Russian Federation

Yuri A. Bunin – MD, PhD, Professor, Chair of Cardiology

Barrikadnaya ul. 2/1, Moscow, 123995



S. A. Miklisanskaya
Russian Medical Academy of Continuous Professional Education
Russian Federation

Sofya V. Miklisanskaya – MD, PhD, Assistant, Chair of Cardiology

Barrikadnaya ul. 2/1, Moscow, 123995



V. V. Chigineva
Russian Medical Academy of Continuous Professional Education
Russian Federation

Victoria V. Chigineva – MD, PhD, Associate Professor, Chair of Cardiology

Barrikadnaya ul. 2/1, Moscow, 123995



E. A. Zolozova
Russian Medical Academy of Continuous Professional Education
Russian Federation

Elena A. Zolozova – MD, PhD, Associate Professor, Chair of Cardiology

Barrikadnaya ul. 2/1, Moscow, 123995



References

1. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting withST-segment elevation. Eur Heart J. 2018;39:119-77. doi: 10.1093/eurheartj/ehx393.

2. Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial fibrillation in acute myocardial infarction. Eur Heart J. 2009;30:1038-45. doi: 10.1093/eurheartj/ehn579.

3. Jabre P., Jouven X., Adnet F. et al. Atrial fibrillation and death аfter myocardial infarction: a community study. Circulation. 2011;123:2094-100. doi: 10.1161/CIRCULATIONAHA.110.990192.

4. Jabre P., Roder V.L., Murad M.H. et al. Mortality associated with atrial fibrillation in patients with myocardial infarction. Circulation. 2011;123:1587-93. doi.org/10.1161/CIRCULATIONAHA. 110.986661.

5. Crenshow B.S., Ward S.R., Granger C.B. et al. Atrial fibrillation in the setting of acute myocardial infarction. J Am Coll Cardiol. 1997;30:406-13.

6. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA and EAPCI task force. Europace. 2014;16:1655-673. doi: 10.1093/europace/euu208.

7. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J. Am. Coll. Cardiol. 2014;64(21):e1-e76. doi: 10.1016/j.jacc.2014.03.022.

8. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-60. doi.org/10.1093/eurheartj/ehx419.

9. Risius T., Mortensen K., Schwermer T.F. et al.Comparison of anterio-lateral versus anterio-posterior electrode position for biphasic external cardioversion of atrial flutter. Am J Cardiol. 2009;104:154750. doi: 10.1016/j.amjcard.2009.07.027.

10. Manegold J.C., Israel C.W., Ehrlich J.R. et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator. Eur Heart J. 2007;28:1731-8. doi: 10.1093/eurheartj/ehm211.

11. Priori S.G., Blomstrom-Lundgvist C., Mazzanti A. et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2015;36:2793-867. doi: 10.1093/europace/euv319.

12. Piccini J.P., Schulte P.J., Pieper K.S. et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med. 2011;39:78-83. doi: 10.1097/CCM.0b013e3181fd6ad7.

13. He X.Z., Zhou S.H., Wan X.H. et al. The effect early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome. Clin Cardiol. 2011;34:59-63. doi: 10.1002/clc.20818.

14. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867. doi: 10.1093/eurheartj/ ehv316.

15. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127:e362-e425. doi: 10.1161/CIR.0b013e3182742cf6.

16. Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-12. doi: 10.1056/NEJM198908103210629.

17. The cardiac arrhythmia suppression trial II investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327(4):227-33. doi: 10.1056/NEJM199207233270403.

18. Teo K.K., Yusuf S., Furberg C.D. Effects prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 1993;270(13):1589-95.

19. Antman E.M. ST-elevation myocardial infarction: management. In Braunwald E., Zipes L., Libby P., Bonow R. (eds). Heart disease. Philadelphia: W.B. Saunders company; 2005. P.1167-1226.

20. Bunin Y.A. The possibilities of antiarrhythmic therapy in primary prevention of death in patients with ventricular arrhythmias. Rational Pharmacotherapy in Cardiology. 2010;6(6):870-5. (In Russ.)

21. Bardy G.H., Lee K.L., Mark D.B. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. doi: 10.1056/NEJMoa043399.

22. Boutitie F., Boissel J.P., Connoly S.J. et al. Amiodarone interaction with beta-blokers: analysis of the merged EMIAT and CAMIAT detabases. Circulation. 1999;99:2268-75. doi: 10.1161/01.CIR. 99.17.2268.

23. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. ACC (2017). J Am Coll Cardiol. 2017 Oct 25. pii: S07351097(17)41306-4. doi: 10.1016/j.jacc.2017.10.054.


For citation:


Bunin Y.A., Miklisanskaya S.A., Chigineva V.V., Zolozova E.A. Atrial Fibrillation and Ventricular Arrhythmias in ST Segment Elevation Myocardial Infarction: Possibilities of Pharmacotherapy and Non-Pharmacological Treatment. Rational Pharmacotherapy in Cardiology. 2018;14(4):605-611. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-4-605-611

Views: 124


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)